Publications by authors named "E Cousin"
Drugs anticipated to be selected for the Medicare Drug Price Negotiation Program in 2025.
J Manag Care Spec Pharm
November 2024
Background: The Centers for Medicare and Medicaid Services (CMS) recently announced the Maximum Fair Price for the first 10 Medicare Part D drugs selected for price negotiation. By February 2025, CMS should announce the list of Part D drugs to be negotiated with implementation of the negotiated prices in 2027.
Objective: To identify up to 15 Medicare Part D single-source drugs anticipated to be selected by CMS for price negotiation in 2025.
Article Synopsis
- Chagas disease (CD) is a growing global health concern, particularly among Latin American migrants in non-endemic countries, prompting a systematic review to determine its prevalence in this population.* -
- Out of 1474 articles screened, 51 studies were included, indicating a pooled CD prevalence of 3.5% among Latin American migrants, with higher rates in specific subgroups such as unselected populations (11.0%) and pregnant women (3.7%).* -
- The research highlights the importance of screening among Latin American migrants and reveals significant levels of congenital transmission at 4.4%, emphasizing the need for public health strategies in non-endemic regions.*
Article Synopsis
- MRD monitoring is essential for managing blood cancers, and while traditional methods use specific molecular targets, new research identifies additional fusion transcripts as potential markers for MRD.
- A study compared a focused RNA-seq method (FusionPlex) with a comprehensive RNA-seq approach (Advanta RNA-Seq XT) and found both methods had 100% agreement in detecting known fusions and good correlation in gene expression levels.
- In a trial with 126 patients, the targeted RNA-seq identified fusion transcripts in nearly half of the cases, leading to the development of specialized digital PCR tests for rare fusions, suggesting a potential shift in MRD evaluation techniques.